Evidence map›Paper›PMID 30383650›Full record

Observational studyMedicine2018

Successful treatment of disseminated intravascular coagulation by recombinant human soluble thrombomodulin in patients with acute myeloid leukemia.

Miyuki Ookura, Naoko Hosono, Toshiki Tasaki, Kana Oiwa, Kei Fujita, Kazuhiro Ito, Shin Lee, Yasufumi Matsuda, Mihoko Morita, Katsunori Tai and 5 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Acute promyelocytic leukemia withOncology letters · 2024
    Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Miyuki OokuraDepartment of Hematology and Oncology, Faculty of Medical Science, University of Fukui.
Naoko HosonoDepartment of Hematology and Oncology, Faculty of Medical Science, University of Fukui.
Toshiki TasakiDepartment of Hematology and Oncology, Faculty of Medical Science, University of Fukui.
Kana OiwaDepartment of Hematology and Oncology, Faculty of Medical Science, University of Fukui.
Kei FujitaDepartment of Hematology and Oncology, Faculty of Medical Science, University of Fukui.
Kazuhiro ItoDepartment of Hematology and Oncology, Faculty of Medical Science, University of Fukui.
Shin LeeDepartment of Hematology and Oncology, Faculty of Medical Science, University of Fukui.
Yasufumi MatsudaDepartment of Hematology and Oncology, Faculty of Medical Science, University of Fukui.
Mihoko MoritaDepartment of Hematology and Oncology, Faculty of Medical Science, University of Fukui.
Katsunori TaiDepartment of Hematology and Oncology, Faculty of Medical Science, University of Fukui.
Eiju NegoroDepartment of Hematology and Oncology, Faculty of Medical Science, University of Fukui.
Shinji KishiDepartment of Health and Nutrition, Jin-ai University.
Hiromichi IwasakiDivision of Infection Control, University of Fukui Hospital.
Takanori UedaUniversity of Fukui, Japan.
Takahiro YamauchiDepartment of Hematology and Oncology, Faculty of Medical Science, University of Fukui.
University of Fukui · JPJin-ai University · JPUniversity of Fukui Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Disseminated intravascular coagulation (DIC) is a life-threatening condition that frequently occurs in patients with hematologic malignancies. Currently, recombinant human soluble thrombomodulin (rTM) is a therapeutic DIC drug that is manufactured and sold in Japan only. We evaluated the efficacy of rTM compared to that of gabexate mesilate (GM), which was previously used routinely for treating DIC in Japan, in patients with acute myeloid leukemia (AML). This retrospective study enrolled 43 AML patients, including 17 with acute promyelocytic leukemia (APL), that was complicated with DIC. DIC resolution rates in non-APL AML and rTM-treated APL patients were 68.4% and 81.8%, respectively. In non-APL AML patients, the duration of rTM administration was significantly shorter than that of GM (7 vs 11 days), suggesting that rTM could improve DIC earlier than GM, although rTM was used in patients with more severe DIC. Moreover, treatment with rTM significantly improved DIC score, fibrinogen, fibrin/fibrinogen degradation product (FDP), and prothrombin time (PT) ratio. Conversely, treatment with GM only improved the DIC score and FDP. In APL patients, the duration of rTM administration was also significantly shorter than that of GM. No severe side effects associated with the progression of bleeding were observed during rTM administration. These findings suggest that rTM is safe, and its anti-DIC effects are more prompt than GM for treating AML patients with DIC.

Indexed as

AdolescentAgedAged, 80 and overDisseminated Intravascular CoagulationFemaleFibrin Fibrinogen Degradation ProductsFibrinogenGabexateHumansLeukemia, Myeloid, AcuteMaleMiddle AgedProthrombin TimeRecombinant ProteinsRetrospective StudiesThrombomodulinFibrin Fibrinogen Degradation ProductsFibrinogenGabexateRecombinant ProteinsTHBD protein, humanThrombomodulin

Identifiers

PMID30383650
PMCPMC6221668
OpenAlexW2898639290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.